Skip to main content

Table 1 Baseline characteristics between HR and RFA groups

From: Radiofrequency ablation for liver metastases in patients with gastric cancer as an alternative to hepatic resection

Characteristics HR (N = 7) n (%) RFA (N = 11) n (%) P* value
Sex
 Male 5 (71.4) 10 (90.9) 0.280
 Female 2 (28.6) 1 (9.1)  
Age
 <60 2 (28.6) 4 (36.4) 0.732
 ≥60 5 (71.4) 7 (63.6)  
Comorbidity
 No 5 (71.4) 6 (54.5) 0.474
 Yes 2 (28.6) 5 (45.5)  
ECOG PS
 0 7 (100) 4 (36.4) 0.026
 1 0 (0) 5 (45.5)  
 2 0 (0) 2 (18.2)  
Tumor location
 Upper 1/3 0 (0) 1 (9.1) 0.434
 Middle 1/3 2 (28.6) 1 (9.1)  
 Lower 1/3 5 (71.4) 9 (81.8)  
Differentation
 Differentiated 4 (51.7) 7 (63.6) 0.783
 Undifferentiated 3 (42.9) 4 (36.4)  
Leuren
 Intestinal 3 (42.9) 6 (54.5) 0.629
 Diffuse&Mixed 4 (51.7) 5 (45.5)  
Primary Tumor size
 <3 cm 1 (14.3) 1 (9.1) 0.829
 ≥3 cm 6 (85.7) 10 (90.9)  
Lymphatic invasion
 LI (−) 3 (42.9) 1 (9.1) 0.093
 LI (+) 4 (57.1) 10 (90.9)  
Vascular invasion
 VI (−) 4 (57.1) 8 (72.7) 0.494
 VI (+) 3 (42.9) 3 (27.3)  
Perineural invasion
 NI (−) 4 (57.1) 8 (72.7) 0.494
 NI (+) 3 (42.9) 3 (27.3)  
T stage
 T1-2 1 (14.3) 5 (45.5) 0.171
 T3-4 6 (85.7) 6 (54.5)  
N stage
 N0 2 (28.6) 1 (9.1) 0.280
 N1-3 5 (71.4) 10 (90.9)  
AJCC 7th stage
 Stage 1–2 3 (42.9) 5 (45.5) 0.914
 Stage 3-4 4 (57.1) 6 (54.5)  
Chemotherapy
 CTx (−) 1 (14.3) 1 (9.1) 0.732
 CTx (+) 6 (85.7) 10 (90.1)  
Number of metastatic Tumor
 Single 5 (71.4) 8 (72.7) 0.952
 Multiple 2 (28.6) 3 (27.3)  
Size of metastatic Tumor
 <3cm 4 (42.9) 6 (54.5) 0.914
 ≥3cm 3 (57.1) 5 (45.5)  
Lobar distribution
 Unilobar 6 (85.7) 10 (90.9) 0.732
 Bilobar 1 (14.3) 1 (9.1)  
Pre-treatment
 Chemotherapy    
 CTx (−) 7 (100) 7 (63.6) 0.070
 CTx (+) 0 (0) 4 (36.4)  
Post-treatment Chemotherapy
 CTx (−) 1 (14.3) 7 (63.6) 0.040
 CTx (+) 6 (85.7) 4 (36.4)  
Complication
 No 5 (71.4) 11 (100) 0.060
 Yes 2 (28.6) 0 (0)  
  1. HR hepatic resection, RFA radiofrequency ablation, ECOG Eastern Cooperative Oncology Group; PS Performance Status, LI lymphatic invasion, VI venous invasion, NI perineural invasion, CTx chemotherapy
  2. *log-rank test